Hormones and the gut

Holdcroft, Anita

doi:10.1093/bja/85.1.58

Cited by 32 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, elevated E2 levels have been reported to increase the threshold to cutaneous stimuli but decrease the percentage of escape responses to ureteral calculosis (Bradshaw and Berkley 2002). Additionally, nociceptive sensitivity increases when E2 levels are elevated (Holdcroft 2000;Bereiter 2001). Indeed in most clinical studies, women report more severe pain levels, more frequent pain and longer duration of pain than men.…”

Section: Estrogen Receptors and Nociceptive Signaling In Primary Affementioning

confidence: 99%

Primary Afferent Nociceptors and Visceral Pain

Chaban¹

2012

Endometriosis - Basic Concepts and Current Research Trends

View full text Add to dashboard Cite

Section: Estrogen Receptors and Nociceptive Signaling In Primary Affementioning

confidence: 99%

Primary Afferent Nociceptors and Visceral Pain

Chaban¹

2012

Endometriosis - Basic Concepts and Current Research Trends

View full text Add to dashboard Cite

“…First, the incidence of carcinoid tumours diagnosed during life is rising with gastrointestinal carcinoids making up the majority; earlier estimates were of fewer than 2 per 100 000 per year (Godwin 1975, Watson et al 1989, Newton et al 1994) but more recent studies have found rates approaching 3 per 100 000 (Levi et al 1993, 2000, Hemminki & Li 2001a,b, Modlin et al 2003. The changes in incidence may result more from changes in detection than in the underlying burden of disease.…”

Section: Epidemiological Studiesmentioning

confidence: 99%

“…An i.v. infusion of 50 µg/h octreotide, started prior to and continued for at least 48 h after any major intervention, is now standard prophylaxis (Kinney et al 2001); it is also important to avoid drugs that release histamine or activate the sympathetic nervous system (Dougherty & Cronau 1998); adrenoreceptor blockade may also be helpful (Holdcroft 2000). Despite these measures patients may still develop lifethreatening cardiorespiratory complications that can tax even the most experienced anaesthetist, who may have to use α-and β-blocking drugs to avoid severe complications (Holdcroft 2000).…”

Section: Wwwendocrinologyorg 473mentioning

confidence: 99%

“…Whilst relief from intestinal angina may be immediate, little response would be expected from the pain of intestinal obstruction. At an advanced stage, intestinal ischaemia may cause necrosis and perforation of the intestinal wall, also a recognised cause of death in patients with midgut carcinoid (Eckhauser et al 1981 Thompson et al 1985, Moertel et al 1987, Norheim et al 1987, Saha et al 1989, Makridis et al 1990, Ballantyne et al 1992, Soreide et al 1992, Levi et al 1993, 2000, DiSario et al 1994, McDermott et al 1994, Norton 1994, Ahlman 1996, Stinner et al 1996, Wä ngberg et al 1996, Burke et al 1997, Cunningham et al 1997, Modlin & Sandor, 1997, Soga 1997, 1998a,b, Sandor & Modlin 1998, Shebani et al 1999, Onaitis et al 2000, Quaedvlieg et al 2001, McCusker et al 2002, Talamonti et al 2002, Modlin et al 2003. 2 Approximate percentage survivals in selected patients from collected publications (Bechstein & Neuhaus 1994, Lang et al 1997, Le Treut et al 1997, Chen et al 1998, Lehnert, 1998, Chamberlain et al 2000, Yao et al 2001).…”

Section: Mesenteric Metastases Natural Historymentioning

confidence: 99%

See 1 more Smart Citation

Surgery for midgut carcinoid.

Doran¹,

Williams²,

Vora³

et al. 2003

Endocrine-Related Cancer

View full text Add to dashboard Cite

Many clinicians prefer to avoid surgery in patients with carcinoid neoplasia, because of its slow growth and relatively favourable prognosis. Nevertheless, the commonest cause of death in patients with carcinoid is advanced metastatic disease, and both clinical and epidemiological data indicate that the more effectively the disease is ablated, the more long-lasting the benefit. Multidisciplinary management of patients with carcinoid must consider inherited risk, possible multiple carcinoids and/ or synchronous non-carcinoid cancer, and the use of a range of investigations that also evaluate the 10% of patients with carcinoid syndrome with or without valvular heart disease. Although primary size is correlated with the presence of nodal with or without liver metastases, carcinoid tumours < 1 cm in diameter may be metastatic at presentation, particularly those arising within the small intestine. In the jejunum and ileum, resection of all sizes of carcinoid with local and regional nodes is preferred, to prevent nodal dissemination causing mesenteric ischaemia with or without infarction. Resection of nodal metastases should be undertaken in those with persistent or recurrent nodal disease if possible. Appendiceal and right colonic carcinoids are most effectively treated by right hemicolectomy with local and regional nodal clearance, as for adenocarcinoma. However, for most appendiceal carcinoids which are < 1 cm in diameter and non-invasive, appendicectomy alone is sufficient. For appendiceal carcinoids 1-2 cm in diameter, histopathological assessment helps to determine the need for hemicolectomy. Liver resection has been followed by prolonged 5 year survival in several series and is recommended in appropriate patients to attempt cure or to debulk metastatic disease. Liver transplantation has had only qualified success in highly selected patients without extra-hepatic disease in whom other therapies have failed.

show abstract

“…(Holdcroft, 2000) Somatostatin analogues can inhibit hormone secretion and lower the level of peripheral serotonin. (Kvols et al, 1986) Theoretically, Somatostatin analogue should be helpful in preventing carcinoid crisis.…”

Section: Introductionmentioning

confidence: 99%

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Guo

Tang²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. In the era of booming anti-tumor therapeutics, this has become more important since associated stresses can trigger carcinoid crisis. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before intervention procedures for functioning NETs. However, the efficacy is still controversial. The aim of this article is to review efficacy of SSTA for preventing carcinoid crisis. Materials and Methods: PubMed, Cochrane Controlled trials Register, and EMBASE were searched using 'carcinoid crisis' as a search term combining terms with 'somatostatin'; 'octreotide'; 'lanreotide' and 'pasireotide' until December 2013. Results: Twenty-eight articles were retrieved with a total of fifty-three unique patients identified for carcinoid crisis. The most common primary sites of NETs were the small intestine and respiratory tract. The triggering factors for carcinoid crisis included anesthesia/ surgery (63.5%), interventional therapy (11.5%), radionuclide therapy (9.6%), examination (7.7%), medication (3.8%), biopsy (2%) and spontaneous (2%). No randomized controlled trials (RCTs) were identified and two case-control studies were included to assess the efficacy of SSTA for preventing carcinoid crisis by meta-analysis. The overall pooled risk of perioperative carcinoid crisis was similar despite the prophylactic administration of SSTA (OR 0.44, 95% CI: 0.14 to 1.35, p=0.15). Conclusions: SSTA wasnot helpful for preventing carcinoid crisis based on a meta-analysis of retrospective studies. Attentive monitoring and careful intervention are essential. Future studies with better quality are needed to clarify any effect of SSTA for preventing carcinoid crisis.

show abstract

Hormones and the gut

Cited by 32 publications

References 45 publications

Primary Afferent Nociceptors and Visceral Pain

Primary Afferent Nociceptors and Visceral Pain

Surgery for midgut carcinoid.

Somatostatin Analogues Do Not Prevent Carcinoid Crisis

Contact Info

Product

Resources

About